Tyrosine Kinase Inhibitor Induced Pulmonary Artery Hypertension: Reversible with Ponatinib?
Serkan Gokaslan, Ersel Onrat, Cigdem Özer Gokaslan, Ibrahim Etem Dural
International Journal of Medical and Pharmaceutical Case Reports · pp. 1–4 · Published 12 Jun 2017
10.9734/IJMPCR/2017/34110Abstract
Pulmonary arterial hypertension (PAH) is a disease associated with progressive and comprehensive vascular remodeling of small pulmonary arteries. The prognosis of Chronic myelogenous leukemia (CML) has been improved by tyrosine kinase inhibitors (TKIs), which inhibit BCR/ABL kinase pathway. Most of the TKIs induced PAH is limited almost exclusively to dasatinib until now. There was only one report about, PAH was caused by the novel TKI ponatinib. We present a 73 years old-female patient with chronic myeloid leukemia, who had PAH after approximately 72 months with prior exposure to dasatinib. Dasatinib was replaced by nilotinib in this patient. Nilotinib was used 11 months for CML treatment, but no recovery was seen with also this TKI. Finally, ponatinib therapy was started for CML. Signs and symptoms of PAH improved with institution of ponatinib therapy. Therefore we report that the patient with dasatinib induced PAH did not recover after institution of nilotinib as a TKI instead of dasatinib but improved with ponatinib treatment using for CML.
References (15)
- 1 Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia [DOI]
- 2 Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia [DOI]
- 3 Cellular and molecular pathobiology of pulmonary arterial hypertension [DOI]
- 4 Pulmonary Arterial Hypertension in Patients Treated by Dasatinib [DOI]
- 5 Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure [DOI]
- 6 Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension [DOI]
- 7 Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia [DOI]
- 8 Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient [DOI]
- 9 Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia [DOI]
- 10 Possible role of imatinib in clinical pulmonary veno-occlusive disease: Fig. 1— [DOI]
- 11 Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia [DOI]
- 12 Pulmonary hypertension associated with ponatinib therapy [DOI]
- 13 Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors [DOI]
- 14 Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia [DOI]
- 15 Drug-induced Respiratory Disease [DOI]
Cited by 0
No indexed citations yet.
Related research
- Pulmonary Arterial Hypertension and Cancer: An Update on Their Similarities — shares topic coverage
- Cardiac and Pulmonary Complications in HbE-β Thalassaemia Patients: A Study from West Bengal, Eastern India — shares topic coverage
- Coexistance of Masked Philadelphia Chromosome and BCR-ABL1 Rearrangement with JAK2 (V617F) Point Mutation-A Case Report — shares topic coverage
- Managing Cabozantinib-induced Dysgeusia: Mechanisms, Clinical Impact, and Strategies for Improved Oncology Outcomes — shares topic coverage
Article metrics
Real usage data collected on this platform.
45
Page views
0
PDF downloads
4
Outbound clicks
0
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.